G-H-3 INTERNATIONAL INC
OOTC:GHTI0.00
USD
0.00
(0.00%)
ISIN
US36172E1055
CUSIP
36172E105
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
0.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Flo Ternes
- Full Time Employees
- - -
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 3220 Pepper Lane Las Vegas NV United States 89120
- IPO Date
- Jun 5, 2023
- Website
- gh3.com
- Similar Companies
- Business
- G-H-3 International Inc. develops and markets anti-aging health care products aimed at addressing factors causing aging and bodily deterioration. Its primary product line includes the G-H-3-Plus protocol, which encompasses a comprehensive combination of intravenous treatments, intramuscular injections, prescription medications, vitamins, and skin care products. Operating mainly within the pharmaceuticals and biotechnology sectors, the company serves a health-conscious customer base focused on longevity and wellness. Founded in 1998 and headquartered in Las Vegas, Nevada, G-H-3 International conducts its business activity primarily in the United States. Recent company developments include the introduction of new formulations and expanded service offerings geared toward enhancing anti-aging treatment protocols, reflecting a strategic focus on product innovation and comprehensive health solutions in the biopharmaceutical domain within the last two years. The company remains publicly traded under the ticker GHTI on the over-the-counter markets. G-H-3 International's core activities center on research-driven product manufacturing and marketing designed to address aging-related health concerns with solutions combining medical treatments and consumer health products to attract a broad range of wellness-focused consumers. These efforts align with a strategic emphasis on expanding its presence in the health technology and biopharmaceutical industry segments domestically.